FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer
- Trial
- IMforte
- Drugs
- Zepzelca (lurbinectedin) · Alkylating agent, Tecentriq (atezolizumab) · Anti-PD-L1 antibody, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) · Anti-PD-L1 antibody
- Condition
- Thoracic